Macquarie Group LTD Cellectis S.A. Transaction History
Macquarie Group LTD
- $80.3 Billion
- Q1 2025
A detailed history of Macquarie Group LTD transactions in Cellectis S.A. stock. As of the latest transaction made, Macquarie Group LTD holds 226,875 shares of CLLS stock, worth $437,868. This represents 0.0% of its overall portfolio holdings.
Number of Shares
226,875
Previous 226,875
-0.0%
Holding current value
$437,868
Previous $408,000
31.13%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CLLS
# of Institutions
30Shares Held
15MCall Options Held
0Put Options Held
0-
Ubs Asset Management Americas Inc Chicago, IL4.72MShares$9.11 Million0.0% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR4.72MShares$9.1 Million0.2% of portfolio
-
B Group, Inc. Dallas, TX3.26MShares$6.29 Million3.46% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.78 Million0.0% of portfolio
-
Baillie Gifford & CO139KShares$268,3600.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $87.8M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...